ALTB-268 demonstrated therapeutic potential in murine models of colitis and GvHD, supporting its role as an immune checkpoint enhancer in T cell-mediated inflammatory diseases Findings reinforce ALTB-268’s ability to downregulate T cell effector function and restore immune balance June 23, 2025 -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company developing novel immune checkpoint enhancers to address the unmet need in immunological and inflammatory diseases, with a

Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma Recommendation based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction treatment significantly improved MRD negativity benefit and prolonged PFS compared to VRd alone If approved, it would represent the fourth indication in the EU and second in the front-line setting globally June 23, 2025. The European Medicines Agency’s Committee for Medicinal Products for Huma

June 25, 2025 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the IND application submitted by its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), has been approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to initiate a Phase 1b/2 clinical trial of soquelitinib for the treatment of patients with moderate-to-severe atopic dermatitis in China. Corvus co-found

- Potential Best-In-Class Bispecific Antibody ATI-052 Targets Both Thymic Stromal Lymphopoietin (TSLP) and Interleukin-4 Receptor (IL-4R) - June 23, 2025 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a placebo-controlled Phase 1a/1b program for ATI-052, the Company’s potential best-in-class investigational bispecific anti-TSLP/IL-4R an

60% (12/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2) EO2463 plus R2 was well tolerated in patients with follicular and marginal zone lymphoma EO2463 plus R2 combination treatment resulted in higher-than-expected rates of complete remission so far in this study compared to historical data for R2 alone 23 June, 2025，Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, presented po

The Independent Data Monitoring Committee (“IDMC”) has recommended to continue the study as planned as there are no safety concerns demonstrated in the data reviewed Interim results to date demonstrate GRI-0621 to be safe and well-tolerated in the first 24 patients evaluated 6-week interim biomarker data (n=24) expected in July 2025 and topline data expected in Q3 2025 Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited p

June 26, 2025 -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced that the European Journal of Pediatrics has published the results of a groundbreaking multicenter clinical trial evidencing positive results for the treatment of OSA in children using Vivos’ patented Daytime-Nighttime Appliance (DNA). The study importantly noted that “This is the first study demonstrating that t

June 26, 2025 -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the publication of preclinical research by Christine Chung, MD and her team (the “Chung Lab”) at Moffitt Cancer Center in Tampa, Florida (“Moffitt”), evaluating intratumoral PV-10 in models of head and neck squamous cell carcinoma (“HNSCC”). The study, published in Molecular Cancer Therapeutics, highlights novel mechanistic findings that could support future clinical development of

-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% in LDL, with a well-tolerated safety profile- -Complete Phase 1 data presentation for CTX310 anticipated at a medical meeting in the second half of 2025- -Data update for CTX320™, targeting the LPA gene, now expected in the first half of 2026- -Preclinical in vivo cardiovascular program CTX340™ adva

Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuity Safety profile consistent with previous clinical trials and no treatment-related serious adverse events reported in the study No evidence of tachyphylaxis was observed in this study over the 6-week period Management to Host Webcast and Conference Call Today at 8:00 A.M. ET June 26, 2025 -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing